In this study, we found that treatment with anti-LAG-3 mAb in the “hot Hepa1-6 tumors” could yield additional therapeutic effects, leading to a reduction in tumor volume and prolonged survival time compared with monotherapy or dual combination immunotherapy. The gene discussed is LAG3; the disease is neoplasm.